News stories about Recro Pharma (NASDAQ:REPH) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Recro Pharma earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 46.4582724752062 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s analysis:
Shares of Recro Pharma (NASDAQ REPH) traded up $0.19 during mid-day trading on Tuesday, hitting $10.10. The stock had a trading volume of 349,000 shares, compared to its average volume of 120,129. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $10.59. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50.
A number of analysts have weighed in on REPH shares. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research report on Friday, October 27th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Recro Pharma presently has a consensus rating of “Buy” and an average target price of $11.65.
In other news, major shareholder Healthcare Master Fun Broadfin sold 172,208 shares of the stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $9.45, for a total transaction of $1,627,365.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 544,813 shares of company stock valued at $5,191,579. Company insiders own 21.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Recro Pharma (REPH) Receives Daily News Sentiment Score of 0.17” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/recro-pharma-reph-earning-somewhat-positive-media-coverage-report-finds.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.